Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.20 USD

9.20
1,564,012

+0.24 (2.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $11.01 +1.81 (19.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

by Zacks Equity Research

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

by Zacks Equity Research

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance

by Zacks Equity Research

Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.

Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

by Zacks Equity Research

Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

by Zacks Equity Research

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.

Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings

by Zacks Equity Research

Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.

The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy

Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Emergent Biosolutions (EBS) closed the most recent trading day at $89.87, moving +1.01% from the previous trading session.

Emergent (EBS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.

Sreoshi Bera headshot

Jobless Claims Rise First Time Since March: 5 Defensive Picks

by Sreoshi Bera

The spike in unemployment claims and looming coronavirus fears have made markets volatile, making defensive picks lucrative investment options.

Top Ranked Momentum Stocks to Buy for July 23rd

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd.

Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker

by Zacks Equity Research

Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.

Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.

Top Ranked Momentum Stocks to Buy for July 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st

Here's Why Emergent Biosolutions (EBS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Emergent Biosolutions (EBS) have what it takes to be a top stock pick for momentum investors? Let's find out.

PhaseBio Initiates Phase II Study for Coronavirus Patients

by Zacks Equity Research

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.